BioMarin RareConnections™: Uncommon support for rare disease
BioMarin RareConnections™ is here to help
BioMarin RareConnections™ provides product support services to help patients and caregivers access BioMarin therapies.
If your doctor has prescribed VIMIZIM® (elosulfase alfa), BioMarin RareConnections™ is your starting point. This program provides a wide array of product support services that includes an experienced case manager who will work with you one-on-one, guiding you through your insurance coverage and assistance options, and helping you with your unique needs related to BioMarin therapy.
Easy steps to enroll
Before you start therapy with BioMarin, you will need to complete and sign the BioMarin authorization forms. These forms allow BioMarin and your healthcare team to share information to assist you with access to VIMIZIM and the services to support your treatment.
- Complete the Patient and Providers form online
- Or, download and print the Patient and Providers form
Read, sign, and return them to your doctor or to the BioMarin address printed on the forms.
Contact BioMarin RareConnections™
at 1-866-906-6100 or email us at
VIMIZIM® (elosulfase alfa) is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).
IMPORTANT SAFETY INFORMATION
VIMIZIM is a prescription medicine. Before treatment with VIMIZIM, it is important to discuss your medical history with your doctor. Tell your doctor if you are sick or taking any medication and if you are allergic to any medicines. Also tell your doctor if you are pregnant, planning to become pregnant, or are a nursing mother. Your doctor will decide if VIMIZIM is right for you. If you have questions or would like more information about VIMIZIM, contact your doctor.
Anaphylaxis can occur during any VIMIZIM infusion and up to three hours after any infusion, and hypersensitivity reactions have been observed as early as 30 minutes from the start of infusion but as late as six days after infusion.
Serious and severe reactions can happen with VIMIZIM treatment, including life-threatening allergic reactions (anaphylaxis), hives, swelling, cough, shortness of breath, and flushing. You should receive medication such as antihistamines before VIMIZIM infusions to reduce the risk of reactions. If a reaction occurs, the infusion should be slowed or stopped and you may be given additional medication. If a severe reaction occurs, the infusion should be stopped immediately and you will receive appropriate medical treatment.
If you have acute febrile or respiratory illness at the time of VIMIZIM infusion you may be at higher risk of life-threatening complications from hypersensitivity reactions. If you use supplemental oxygen or continuous positive airway pressure (CPAP) you should have it available during your infusion in the event of a sudden reaction, or extreme drowsiness/sleep from antihistamines.
Spinal cord damage may occur due to the natural MPS IVA disease process. Signs of spinal cord injury include back pain, numbness and paralysis, and loss of bladder and bowel control. Contact your doctor immediately if you develop any of these symptoms.
The most common side effects reported during VIMIZIM infusions included fever, vomiting, headache, nausea, abdominal pain, chills, and fatigue. These are not all of the possible side effects with VIMIZIM. Talk to your doctor if you have any symptoms that bother you or that do not go away.
Call your doctor for medical advice about side effects. You may report side effects to BioMarin Pharmaceutical Inc. at 1-866-906-6100, or FDA at 1-800-FDA-1088 or go to www.fda.gov/medwatch.
For more information, call BioMarin RareConnections™ at 1-866-906-6100.